Linde plc Ordinary Shares (LIN)vsVersamet Royalties Corporation Common Stock (VMET)
LIN
Linde plc Ordinary Shares
$515.73
+0.68%
BASIC MATERIALS · Cap: $241.10B
VMET
Versamet Royalties Corporation Common Stock
$11.16
-5.39%
BASIC MATERIALS · Cap: $1.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Linde plc Ordinary Shares generates 62596% more annual revenue ($34.65B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 20.4%. LIN trades at a lower P/E of 34.6x. LIN earns a higher WallStSmart Score of 62/100 (C+).
LIN
Buy62
out of 100
Grade: C+
VMET
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.3%
Fair Value
$299.00
Current Price
$515.73
$216.73 premium
Intrinsic value data unavailable for VMET.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 28.5%
Keeps 58 of every $100 in revenue as profit
Strong operational efficiency at 90.6%
Revenue surging 594.0% year-over-year
Earnings expanding 573.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LIN
The strongest argument for LIN centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 20.4% and operating margin at 28.5%.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.
Bear Case : LIN
The primary concerns for LIN are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : VMET
The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
LIN profiles as a mature stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 594.0% — sustainability is the question.
LIN generates stronger free cash flow (898M), providing more financial flexibility.
Monitor SPECIALTY CHEMICALS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LIN scores higher overall (62/100 vs 58/100), backed by strong 20.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Linde plc Ordinary Shares
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
Linde plc is a multinational chemical company. It is the largest industrial gas company by market share and revenue. It serves customers in the healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, electronics and water treatment industries. The company's primary business is the manufacturing and distribution of atmospheric gases, including oxygen, nitrogen, argon, rare gases, and process gases, including carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene.
Visit Website →Versamet Royalties Corporation Common Stock
BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.
Compare with Other SPECIALTY CHEMICALS Stocks
Want to dig deeper into these stocks?